Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets.
In the context of an A/H1N1 influenza pandemic situation, this study demonstrates that heterologous vaccination with an AS03-adjuvanted 2008/2009 seasonal trivalent and pandemic H5N1 monovalent split vaccine conferred partial protection in influenza-naïve ferrets after challenge with the influenza pandemic H1N1 A/The Netherlands/602/09 virus. Further, unlike saline control and non-adjuvanted vaccine, it was shown that immunization of naïve ferrets with an AS03-adjuvanted pandemic H1N1 A/California/7/09 influenza split vaccine induced increased antibody response and enhanced protection against the challenge strain, including significant reduction in viral shedding in the upper respiratory tract and reduced lung pathology post-challenge. These results show the need for vaccination with the adjuvanted vaccine to fully protect against viral replication and influenza disease in unprimed ferrets.
GlaxoSmithKline Biologicals, Rixensart, Belgium. benoit.baras@gskbio.com
Benoît
B
Baras
Leon
L
de Waal
Koert J
KJ
Stittelaar
Valérie
V
Jacob
Sandra
S
Giannini
Edwin J B Veldhuis
EJ
Kroeze
Judith M A
JM
van den Brand
Geert
G
van Amerongen
James H
JH
Simon
Emmanuel
E
Hanon
Sally P
SP
Mossman
Albert D M E
AD
Osterhaus
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005289:Ferrets; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology / Q000502:physiology; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology / Q000502:physiology; D007252:Influenza Vaccines / Q000276:immunology*; D008168:Lung / Q000473:pathology / Q000821:virology; D009500:Neutralization Tests; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control*; D019562:Viral Load; D014779:Virus Replication; D017201:Virus Shedding
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines